Replies to post #851 on Synaptogenix Inc (SNPX)

[InTheTrenches]

Not just Dr. Alkon, but other independent, peer-reviewed studies show the false narrative of the amyloid plaque theory:

A study by professor Clive Homes published in the Lancet supports the criticism of the amyloid hypothesis. Homes found, during autopsies of dementia patients who'd undergone treatment for the removal of amyloid plaque, that while some had virtually complete plaque removal, seven of the eight still died with severe end-stage dementia. "In the whole cohort," Homes wrote, "there was no evidence of improved survival or of an improvement in the time to severe dementia" versus the placebo group.

[F1ash]

-----
My question is does AVXL fall into the treating amyloid deposits hypothesis camp or not?
---------
No. Anavex is targeting the Sigma 1 receptor in hopes of restoring cellular homeostasis. Not targeting plaques.

[drbio45]

There is nothing wrong with targeting plaques and tau, if you doing other things also

the problem with the BACE inhibitors and monoclonal antibodies target plaque is that is ALL they do.

Bryostatin activates the enzymes ECE, IDE and neprilysin, which inhibit plaque and inhibits GSK3 beta which inhibits tau formation, but in addition to that increases growth factors to restore synapses.

Multi modal mechanism, not one target

[XenaLives]

No, 2-73 is not a plaque attack drug.... different MOA from NTRP - possibly synergistic.